CAMBRIDGE, Mass., Oct. 1, 2018 /PRNewswire/ -- Torque, an immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor ...
T-cell therapies like Gilead’s Yescarta and Novartis’ Kymriah have generated enthusiasm because of their high response rates in patients with lymphoma and leukemia. But the technology—which involves ...
Torque, a developer of T-cell cancer therapeutics produced through its Deep-Priming™ technology platform said today it has created a manufacturing process that will produce its T-cell cancer therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results